This contract supports the advanced development of ST-246 as a novel therapeutic agent for prevention and post-event therapeutic treatment of smallpox and related orthopoxviruses. This new contract enables the formulation and advanced development of a new ST-246 parenteral drug product as well as new ways to use the existing oral formulation of ST-246 to combat smallpox. Success would significantly enhance the utility of ST-246 and substantially expand the biodefense indications for SIGA's original oral formulation.
